Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 4,333 shares at $32.12 ($139K) on 2026-02-03, disclosed to the SEC on 2026-02-03.
Seasonal sale ($139k) by SVP, CHIEF ACCOUNTING OFFICER — this insider has traded TVTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |
| TVTX | SELL | 2025-11-06 | $2.4M | — | Filing → |